Amneal Pharmaceuticals (AMRX) Capital Leases (2017 - 2026)

Amneal Pharmaceuticals' Capital Leases history runs 10 years deep, the most recent figure standing at $54.9 million for Q1 2026.

• In Q1 2026, Capital Leases fell 3.05% year-over-year to $54.9 million; the TTM figure through Mar 2026 stood at $54.9 million (down 3.05% YoY), while the FY2025 annual figure was $54.9 million, down 3.45% from the prior year.
• Capital Leases was $54.9 million for Q1 2026 at Amneal Pharmaceuticals, roughly flat from $54.9 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $61.3 million in Q3 2022 to a low of $54.9 million in Q1 2026.
• Historically, Capital Leases has averaged $58.2 million across 5 years, with a median of $58.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Capital Leases rose 0.86% in 2022, then retreated 3.75% in 2025.
• A 5-year view of Capital Leases shows it stood at $60.8 million in 2022, then slipped by 3.63% to $58.6 million in 2023, then decreased by 2.86% to $56.9 million in 2024, then decreased by 3.45% to $54.9 million in 2025, then fell by 0.09% to $54.9 million in 2026.
• The last three Capital Leases figures came in at $54.9 million (Q1 2026), $54.9 million (Q4 2025), and $55.7 million (Q3 2025), per Business Quant data.